Purchase this article with an account.
Stephanie Watson, Kenneth Ooi, Frank Billson, Denis Wakefield; Topical atorvastatin for the treatment of dry eye associated with blepharitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6004.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate topical Atorvostatin, a novel ocular therapy, for the treatment of patients with dry eye associated with blepharitis.
10 patients with symptoms and signs of dry eye and blepharitis were enrolled in a prospective pilot study of topical Atorvostatin therapy over 1 month. The primary outcome measure was corneal fluorescein staining.
An improvement in corneal fluorescein staining in the treated eye by more than one point from baseline to completion of the trial at week four was found in 9 of 10 patients (p = 0.007). Topical statin significantly improved the blepharitis score (p = 0.011) and the tear film break-up time (p = 0.005). Subjective dry eye symptoms improved (p = 0.005). There were no serious or irreversible side-effects.
Topical statins are a potential therapy for patients with dry eye and blepharitis. They can be easily manufactured and could be widely available. It may also be of benefit in other dry eye syndromes.
This PDF is available to Subscribers Only